Document Detail

Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects.
MedLine Citation:
PMID:  8303624     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The cysteinyl leukotrienes (LTC4, LTD4, and LTE4) have been shown to mediate airway obstruction evoked by several factors which trigger asthmatic reactions--for example, allergen and exercise. Accordingly, drugs which block the action or formation of these leukotrienes are being evaluated as a new treatment of asthma. Elevated production of leukotrienes has been reported in asthmatic subjects who are intolerant to aspirin and related nonsteroidal anti-inflammatory drugs. In this study the influence of the specific leukotriene receptor antagonist MK-0679 was tested on basal airway function in asthmatic patients with documented aspirin intolerance. METHODS: The eight subjects in the study had a mean baseline FEV1 of 78% predicted (range 58-99%) and six required treatment with inhaled glucocorticosteroids (400-1200 micrograms budesonide/beclomethasone daily). On two separate days the subjects received either 825 mg MK-0679 or placebo, orally in a double blind, randomised, crossover design. RESULTS: The leukotriene antagonist MK-0679 caused bronchodilation which lasted for at least nine hours. The average peak improvement in FEV1 was 18% above the predrug baseline, but the bronchodilator response varied between 34% and 5% and was found to correlate strongly with the severity of asthma and aspirin sensitivity. CONCLUSIONS: The findings indicate that ongoing leukotriene production may be one cause of persistent airway obstruction in aspirin sensitive asthmatic subjects and that they may benefit from treatment with a leukotriene receptor antagonist.
B Dahl?n; D J Margolskee; O Zetterstr?m; S E Dahl?n
Related Documents :
8083384 - Chronopharmacologic issues in space.
24829864 - Evolution of costs of cancer drugs in a portuguese hospital.
197384 - Roles of prostaglandins suggested by the prostaglandin agonist/antagonist actions of lo...
24872894 - Carbon nanotubes: an emerging drug carrier for targeting cancer cells.
8086154 - Cholinesterase activity in sea urchin early embryos may be correlated to the intracellu...
9715784 - Follow-up study of the use of antihypertensive drug treatment and of the population tre...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Thorax     Volume:  48     ISSN:  0040-6376     ISO Abbreviation:  Thorax     Publication Date:  1993 Dec 
Date Detail:
Created Date:  1994-03-10     Completed Date:  1994-03-10     Revised Date:  2010-03-24    
Medline Journal Info:
Nlm Unique ID:  0417353     Medline TA:  Thorax     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1205-10     Citation Subset:  IM    
Department of Thoracic Medicine, Karolinska Hospital, Stockholm, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Airway Obstruction / drug therapy,  physiopathology
Aspirin / adverse effects
Asthma / drug therapy*,  physiopathology
Bronchi / drug effects
Double-Blind Method
Forced Expiratory Volume
Lung / drug effects*,  physiopathology
Middle Aged
Propionates / therapeutic use*
Quinolines / therapeutic use*
SRS-A / antagonists & inhibitors*
Reg. No./Substance:
0/Propionates; 0/Quinolines; 0/SRS-A; 115104-28-4/verlukast; 50-78-2/Aspirin
Comment In:
Thorax. 1993 Dec;48(12):1189-90   [PMID:  8303620 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Histological study of the cranial neural folds of mice genetically liable to exencephaly.
Next Document:  How many times per day should peak expiratory flow rates be assessed when investigating occupational...